Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 264 participants.

Also called NCT04984954

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 264 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04984954
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04984954. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-28 (actual); primary completion 2023-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction
Condition
Angina Pectoris
Condition
Coronary Heart Disease
Condition
X Syndrome, Angina
Condition
Non Obstructive Coronary Artery Disease
Intervention (Drug)
MUSK pill
Lead sponsor
Shanghai Hutchison Pharmaceuticals Limited (class: industry)

Record details

Record id
cardio:ct-nct04984954
Content hash
c7eff207cb2b8b04599a351dfc5fa98c4526c81b9b7899645b9a01e96fc3ccad